$USPH
U S PHYSICAL THERAPY INC /NV

2022 Q4 Form 10-Q Financial Statement

#000114036122040455 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $141.2M $139.6M $123.6M
YoY Change 8.74% 12.96% 15.58%
Cost Of Revenue $113.4M $112.8M $96.09M
YoY Change 10.44% 17.41% 22.41%
Gross Profit $27.83M $26.78M $29.80M
YoY Change 2.35% -10.12% -1.84%
Gross Profit Margin 19.71% 19.19% 24.11%
Selling, General & Admin $11.93M $11.89M $12.87M
YoY Change 11.26% -7.6% 23.72%
% of Gross Profit 42.85% 44.39% 43.18%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.793M $3.652M $3.035M
YoY Change 23.47% 20.33% 10.77%
% of Gross Profit 13.63% 13.64% 10.18%
Operating Expenses $11.93M $11.89M $12.87M
YoY Change 11.26% -7.6% 23.72%
Operating Profit $15.91M $14.90M $16.93M
YoY Change -3.45% -12.03% -15.16%
Interest Expense -$1.978M -$1.644M -$210.0K
YoY Change 5105.26% 682.86% -30.0%
% of Operating Profit -12.44% -11.04% -1.24%
Other Income/Expense, Net -$256.0K $2.785M $1.216M
YoY Change 129.03%
Pretax Income $4.560M $16.04M $17.94M
YoY Change -75.2% -10.6% -10.5%
Income Tax $1.212M $3.215M $3.815M
% Of Pretax Income 26.58% 20.05% 21.27%
Net Earnings -$145.0K $9.557M $10.01M
YoY Change -101.42% -4.52% -8.31%
Net Earnings / Revenue -0.1% 6.85% 8.1%
Basic Earnings Per Share $0.72 $0.66
Diluted Earnings Per Share -$0.01 $735.1K $0.66
COMMON SHARES
Basic Shares Outstanding 13.00M 13.00M 12.91M
Diluted Shares Outstanding 13.00M 12.91M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $31.59M $37.91M $19.19M
YoY Change 10.6% 97.59% -36.25%
Cash & Equivalents $31.59M $37.91M $19.19M
Short-Term Investments
Other Short-Term Assets $11.07M $6.085M $3.687M
YoY Change 164.57% 65.04% 15.22%
Inventory
Prepaid Expenses
Receivables $51.93M $68.89M $56.55M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $111.3M $112.9M $79.42M
YoY Change 16.92% 42.14% -3.85%
LONG-TERM ASSETS
Property, Plant & Equipment $24.75M $126.0M $115.0M
YoY Change 7.7% 9.55% 14.64%
Goodwill $494.1M $449.5M $374.0M
YoY Change 13.67% 20.18% 11.01%
Intangibles $108.8M $93.70M $60.09M
YoY Change 25.9% 55.94% 11.15%
Long-Term Investments $12.13M $11.98M
YoY Change -0.69%
Other Assets $4.149M $5.619M $1.553M
YoY Change 162.93% 261.82% 3.53%
Total Long-Term Assets $746.9M $686.8M $550.7M
YoY Change 14.16% 24.72% 11.74%
TOTAL ASSETS
Total Short-Term Assets $111.3M $112.9M $79.42M
Total Long-Term Assets $746.9M $686.8M $550.7M
Total Assets $858.2M $799.7M $630.1M
YoY Change 14.51% 26.92% 9.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.504M $7.674M $1.532M
YoY Change 0.51% 400.91% 39.27%
Accrued Expenses $37.41M $66.32M $50.27M
YoY Change -18.14% 31.94% -16.55%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $7.863M $7.490M $672.0K
YoY Change 847.35% 1014.58% -86.56%
Total Short-Term Liabilities $85.49M $81.49M $81.67M
YoY Change 2.41% -0.22% -12.37%
LONG-TERM LIABILITIES
Long-Term Debt $175.8M $146.7M $35.27M
YoY Change 49.53% 315.96% 369.64%
Other Long-Term Liabilities $13.03M $80.93M $77.65M
YoY Change 77.39% 4.23% 28.35%
Total Long-Term Liabilities $188.9M $227.6M $35.27M
YoY Change 51.17% 545.46% 369.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $85.49M $81.49M $81.67M
Total Long-Term Liabilities $188.9M $227.6M $35.27M
Total Liabilities $373.6M $482.6M $340.3M
YoY Change 25.79% 41.8% 9.6%
SHAREHOLDERS EQUITY
Retained Earnings $232.9M $235.7M $219.3M
YoY Change 3.81% 7.45%
Common Stock $152.0K $152.0K
YoY Change 0.66%
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M $31.63M
YoY Change 0.0%
Treasury Stock Shares $2.215M $2.215M
Shareholders Equity $315.8M $317.1M $289.8M
YoY Change
Total Liabilities & Shareholders Equity $858.2M $799.7M $630.1M
YoY Change 14.51% 26.92% 9.51%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$145.0K $9.557M $10.01M
YoY Change -101.42% -4.52% -8.31%
Depreciation, Depletion And Amortization $3.793M $3.652M $3.035M
YoY Change 23.47% 20.33% 10.77%
Cash From Operating Activities $17.30M $13.73M $24.95M
YoY Change 8.76% -44.97% -4.94%
INVESTING ACTIVITIES
Capital Expenditures $958.0K -$2.721M -$2.695M
YoY Change -143.45% 0.96% 213.37%
Acquisitions
YoY Change
Other Investing Activities -$42.43M -$11.62M -$8.188M
YoY Change -45.37% 41.88% 106.25%
Cash From Investing Activities -$43.39M -$14.34M -$10.88M
YoY Change -45.68% 31.75% 124.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.77M -10.05M -15.29M
YoY Change -73.05% -34.3% -56.11%
NET CHANGE
Cash From Operating Activities 17.30M 13.73M 24.95M
Cash From Investing Activities -43.39M -14.34M -10.88M
Cash From Financing Activities 19.77M -10.05M -15.29M
Net Change In Cash -6.320M -10.66M -1.231M
YoY Change -167.38% 765.8% -90.84%
FREE CASH FLOW
Cash From Operating Activities $17.30M $13.73M $24.95M
Capital Expenditures $958.0K -$2.721M -$2.695M
Free Cash Flow $16.34M $16.45M $27.64M
YoY Change -9.77% -40.49% 1.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Address City Or Town
EntityAddressCityOrTown
HOUSTON
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77042
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
297-7000
dei Security12b Title
Security12bTitle
Common Stock, $.01 par value
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-11151
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0364866
dei Entity Address Address Line1
EntityAddressAddressLine1
1300 WEST SAM HOUSTON PARKWAY SOUTH
dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 300
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
65000
CY2021Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
58000
us-gaap Interest And Other Income
InterestAndOtherIncome
790000
us-gaap Interest And Other Income
InterestAndOtherIncome
158000
CY2022Q3 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
785000
CY2021Q3 usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
0
usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
771000
usph Gain Loss On Revaluation Of Put Right Liability
GainLossOnRevaluationOfPutRightLiability
0
CY2022Q3 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
2013000
CY2021Q3 usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
268000
usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
3540000
usph Interest Expense Debt And Other
InterestExpenseDebtAndOther
751000
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.2555
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.2555
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2555
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
15990000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
13934000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
150000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
usph Payment Of Medicare Accelerated And Advance Funds
PaymentOfMedicareAcceleratedAndAdvanceFunds
0
usph Payment Of Medicare Accelerated And Advance Funds
PaymentOfMedicareAcceleratedAndAdvanceFunds
14054000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1779000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
12000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
7000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
308933000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2022Q3 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-147000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1802000
CY2022Q3 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
0
CY2022Q3 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
94000
CY2022Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
5331000
CY2022Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1519000
CY2022Q3 usph Deferred Taxes Related To Redeemable Non Controlling Interest Temporary Equity
DeferredTaxesRelatedToRedeemableNonControllingInterestTemporaryEquity
643000
CY2022Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
0
CY2022Q3 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1227000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
9557000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4819000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
318604000
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
15990000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
3990000
usph Deferred Taxes Related To Redeemable Non Controlling Interest Temporary Equity
DeferredTaxesRelatedToRedeemableNonControllingInterestTemporaryEquity
2129000
us-gaap Stockholders Equity Other
StockholdersEquityOther
697000
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
3288000
us-gaap Net Income Loss
NetIncomeLoss
29551000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4424000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
318604000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
284811000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2021Q3 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-1542000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2877000
CY2021Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
4906000
CY2021Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1730000
CY2021Q3 us-gaap Stockholders Equity Other
StockholdersEquityOther
-4000
CY2021Q3 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1509000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
10009000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
290617000
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
277630000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6280000
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
13934000
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
4912000
usph Short Swing Profit Settlement
ShortSwingProfitSettlement
20000
us-gaap Stockholders Equity Other
StockholdersEquityOther
-20000
usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
4194000
us-gaap Net Income Loss
NetIncomeLoss
30618000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
290617000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
us-gaap Number Of Businesses Acquired
NumberOfBusinessesAcquired
614
CY2022Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
40
usph Number Of Closed Clinics
NumberOfClosedClinics
5
usph Number Of Sold Clinics
NumberOfSoldClinics
5
usph Percentage Of General Partnership Interest Owned
PercentageOfGeneralPartnershipInterestOwned
0.01
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
usph Number Of Regions
NumberOfRegions
6
usph Number Of Regions
NumberOfRegions
6
usph Number Of Regions
NumberOfRegions
6
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022Q3 us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
us-gaap Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations
InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations
0
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
800000
CY2022Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2800000
usph Resolution Of Payor Matter
ResolutionOfPayorMatter
1216000
usph Percentage Of Payment For Outpatient Therapy Services
PercentageOfPaymentForOutpatientTherapyServices
0.85
CY2022Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2555
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
643000
dei Amendment Flag
AmendmentFlag
false
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-113000
us-gaap Unrealized Gain Loss On Cash Flow Hedging Instruments
UnrealizedGainLossOnCashFlowHedgingInstruments
5942000
us-gaap Unrealized Gain Loss On Cash Flow Hedging Instruments
UnrealizedGainLossOnCashFlowHedgingInstruments
0
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
usph Proceeds From Sales Of Non Controlling Interest Permanent
ProceedsFromSalesOfNonControllingInterestPermanent
0
usph Proceeds From Sales Of Non Controlling Interest Permanent
ProceedsFromSalesOfNonControllingInterestPermanent
131000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates
ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
401000
us-gaap Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates
ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
69000
dei Entity Registrant Name
EntityRegistrantName
U S PHYSICAL THERAPY INC /NV
dei Entity Central Index Key
EntityCentralIndexKey
0000885978
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2022Q3 usph Resolution Of Payor Matter
ResolutionOfPayorMatter
0
CY2021Q3 usph Resolution Of Payor Matter
ResolutionOfPayorMatter
1216000
usph Resolution Of Payor Matter
ResolutionOfPayorMatter
0
dei Trading Symbol
TradingSymbol
USPH
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13001589
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
297181000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-144000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5462000
usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
707000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
454000
CY2021Q3 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
668000
CY2021Q3 usph Sale Of Non Controlling Interest Net Of Tax And Purchases
SaleOfNonControllingInterestNetOfTaxAndPurchases
261000
usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
-8852000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
668000
usph Sale Of Non Controlling Interest Net Of Tax And Purchases
SaleOfNonControllingInterestNetOfTaxAndPurchases
261000
usph Estimated Percentage Of Decrease In Payment
EstimatedPercentageOfDecreaseInPayment
0.035
CY2021Q4 usph Percentage Of Reduction In Medicare Payments For Services Performed By A Physical Or Occupational Therapist
PercentageOfReductionInMedicarePaymentsForServicesPerformedByAPhysicalOrOccupationalTherapist
0.15
usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
usph Reduction In Medicare Spending Percentage
ReductionInMedicareSpendingPercentage
0.02
CY2022Q3 us-gaap Interest Rate Derivative Assets At Fair Value
InterestRateDerivativeAssetsAtFairValue
5900000
CY2022Q3 us-gaap Unrealized Gain Loss On Interest Rate Cash Flow Hedges Pretax Accumulated Other Comprehensive Income Loss
UnrealizedGainLossOnInterestRateCashFlowHedgesPretaxAccumulatedOtherComprehensiveIncomeLoss
4800000
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Reduction In Combined Physical Therapy Speech Language Pathology Expenses
ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses
3000
usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1
usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.50
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Use of Estimates</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">I<span style="font-size: 10pt; font-family: 'Times New Roman';">n preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, goodwill impairment, tradenames and other intangible assets, allocations of purchase price, allowance for credit losses, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates</span>.</div>
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
900000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
139602000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
125893000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
411962000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
365189000
CY2013Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2015Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2018Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2022Q3 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2022Q3 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q2 usph Percentage Of Payment Reduction Waived Through Enacted Legislation
PercentageOfPaymentReductionWaivedThroughEnactedLegislation
0.02
usph Extension Term For Sequester Relief Applied To All Medicare Payments
ExtensionTermForSequesterReliefAppliedToAllMedicarePayments
P3M
CY2021Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period One
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodOne
0.02
CY2021Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
CY2019Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
CY2020Q4 usph Percentage Of Sequester Relief Applied To All Medicare Payments Through Period Two
PercentageOfSequesterReliefAppliedToAllMedicarePaymentsThroughPeriodTwo
0.01
usph Percentage Of Increase In Payment Adjustment For Therapists Participating In Merit Based Incentive Payment System
PercentageOfIncreaseInPaymentAdjustmentForTherapistsParticipatingInMeritBasedIncentivePaymentSystem
0.01
usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
usph Net Revenue From Medicare
NetRevenueFromMedicare
115100000
usph Net Revenue From Medicare
NetRevenueFromMedicare
98300000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
9557000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
10009000
us-gaap Net Income Loss
NetIncomeLoss
29551000
us-gaap Net Income Loss
NetIncomeLoss
30618000
CY2022Q3 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-196000
CY2021Q3 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-2070000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-193000
usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-11889000
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2555
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.2555
CY2022Q3 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-50000
CY2021Q3 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-529000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-49000
usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-3038000
CY2022Q3 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
9411000
CY2021Q3 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
8468000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
29407000
usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
21767000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.72
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.72
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.66
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.69
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13001000
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13001000
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12909000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12909000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12979000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12979000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12894000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12894000
CY2021Q4 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
117587000
CY2021Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0
CY2021Q4 us-gaap Goodwill
Goodwill
434679000
CY2020Q4 us-gaap Goodwill
Goodwill
345646000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
19522000
CY2021 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
89746000
us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-4653000
CY2021 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
-713000
CY2022Q3 us-gaap Goodwill
Goodwill
449548000
CY2021Q4 us-gaap Goodwill
Goodwill
434679000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
93697000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
86382000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1533000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
995000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4811000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2732000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
16588000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23569000
CY2022Q3 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
7875000
CY2021Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
6649000
CY2022Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2888000
CY2021Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
1984000
CY2022Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
238000
CY2021Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
498000
CY2022Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
144000
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2716000
CY2022Q3 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
520000
CY2021Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
1000000
CY2022Q3 us-gaap Litigation Reserve Current
LitigationReserveCurrent
0
CY2021Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
2750000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5531000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6539000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33784000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45705000
CY2022Q1 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
2750000
CY2021 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
2600000
CY2022Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
156122000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1942000
CY2022Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
154180000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
118417000
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
0
CY2021Q4 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
118417000
CY2022Q3 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
7898000
CY2022Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
408000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
7490000
CY2021Q4 usph Debt Instrument Face Amount Current
DebtInstrumentFaceAmountCurrent
830000
CY2021Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
0
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
830000
CY2022Q3 usph Debt Instrument Face Amount Noncurrent
DebtInstrumentFaceAmountNoncurrent
148224000
CY2022Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1534000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
146690000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
117587000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
8870000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
8114000
us-gaap Operating Lease Cost
OperatingLeaseCost
25974000
us-gaap Operating Lease Cost
OperatingLeaseCost
23738000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
210000
CY2021Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
440000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
790000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1169000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1913000
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1670000
us-gaap Variable Lease Cost
VariableLeaseCost
5839000
us-gaap Variable Lease Cost
VariableLeaseCost
4908000
CY2022Q3 us-gaap Lease Cost
LeaseCost
10993000
CY2021Q3 us-gaap Lease Cost
LeaseCost
10224000
us-gaap Lease Cost
LeaseCost
32603000
us-gaap Lease Cost
LeaseCost
29815000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
9139000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
8354000
us-gaap Operating Lease Payments
OperatingLeasePayments
26697000
us-gaap Operating Lease Payments
OperatingLeasePayments
24724000
CY2022Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8011000
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13269000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
29618000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
34112000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
9151000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
33724000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
27159000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
19573000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
12748000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
13399000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
115754000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6307000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
109447000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M12D
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.027
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.029
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.027
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.029
CY2022Q3 us-gaap Revenues
Revenues
139602000
CY2021Q3 us-gaap Revenues
Revenues
125893000
us-gaap Revenues
Revenues
411962000
us-gaap Revenues
Revenues
365189000
CY2022Q3 us-gaap Gross Profit
GrossProfit
26784000
CY2021Q3 us-gaap Gross Profit
GrossProfit
29799000
us-gaap Gross Profit
GrossProfit
84193000
us-gaap Gross Profit
GrossProfit
89999000
CY2022Q3 us-gaap Assets
Assets
799708000
CY2021Q3 us-gaap Assets
Assets
630098000
CY2009Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
859499
usph Additional Estimated Repurchase Of Common Stock
AdditionalEstimatedRepurchaseOfCommonStock
197316
CY2022Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
76.02
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2022Q3 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0

Files In Submission

Name View Source Status
0001140361-22-040455-index-headers.html Edgar Link pending
0001140361-22-040455-index.html Edgar Link pending
0001140361-22-040455.txt Edgar Link pending
0001140361-22-040455-xbrl.zip Edgar Link pending
brhc10043464_10q.htm Edgar Link pending
brhc10043464_ex31-1.htm Edgar Link pending
brhc10043464_ex31-2.htm Edgar Link pending
brhc10043464_ex32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
brhc10043464_10q_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20220930.xsd Edgar Link pending
usph-20220930_def.xml Edgar Link unprocessable
usph-20220930_lab.xml Edgar Link unprocessable
usph-20220930_pre.xml Edgar Link unprocessable
usph-20220930_cal.xml Edgar Link unprocessable